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Chronic kidney disease (CKD) and end-stage renal disease (ESRD) 
are important causes of morbidity and mortality in South Africa 
(SA). The close link between CKD and the growing burden of 
non-communicable diseases further underscores the importance of 
CKD. Although renal replacement therapy in the form of dialysis is 
a life-saving treatment, access to dialysis in the SA public sector has 
remained largely unchanged since the advent of democracy.[1] The 
situation is worse in rural provinces such as Limpopo, where there is 
only one dialysis centre in the public sector. Renal failure is reported 
to be among the top 10 causes of natural deaths in Limpopo. [2] 
The cost of dialysis is a key factor preventing access to it. There is 
therefore a need to identify strategies to make dialysis more accessible 
and cost-effective.
The National Department of Health convened a summit in 2015 to 
discuss the challenges posed by CKD in SA and propose solutions. [3] 
The meeting recommended a call to increase the dialysis rate from 
164 to 250 per million population (pmp) by 2025.[3] The use of 
private-public partnerships (PPPs) was among the strategies proposed 
to achieve the target figure. National Treasury defines a PPP as an 
agreement between the public and private sectors where the private 
sector is contracted to perform an institutional function on behalf of 
the public sector in return for a benefit.[4] The Pietersburg Hospital 
dialysis unit in the city of Polokwane is the first and only renal dialysis 
unit in the public health sector in Limpopo, and the only PPP renal 
unit in SA. It is important to explore the cost implications of using the 
PPP approach for the provision of renal dialysis services.
Few detailed costing studies on renal dialysis have been conducted 
in sub-Saharan Africa.[5] In 2010, Abu-Aisha et al.[6] estimated 
the annual cost of dialysis per patient in SA to be USD12 000 and 
USD7 000 for peritoneal dialysis (PD) and haemodialysis (HD), 
respectively.[6] A survey of renal replacement in Africa, conducted 
using interviews with key informants in 2007, estimated the annual 
cost of HD and PD to be USD20 000 and USD30 000, respectively.[7] 
These cost estimates omitted details of the costing approach and the 
cost components included. More detailed cost studies will provide the 
full cost of dialysis and identify the cost drivers.
Objectives
To estimate the direct cost of providing PD and HD using the PPP 
approach at the PPP dialysis unit in Polokwane.
Methods
The study was conducted at Pietersburg Hospital, a 500-bed tertiary 
institution in Polokwane. Together with Mankweng Hospital, 
Pietersburg Hospital is responsible for providing tertiary services to 
the population of Limpopo. Limpopo is a mostly rural province with 
an estimated population of 5.8 million spread across five districts. [8] 
The renal dialysis unit at Pietersburg Hospital is the only dialysis 
centre for an estimated 5.3 million uninsured individuals who 
depend on the public health sector.[8]
Prior to 2006, chronic dialysis patients were referred to Dr George 
Mukhari Hospital in Pretoria for dialysis treatments. The Limpopo 
Provincial Department of Health (LDoH) and a private partner 
signed a PPP agreement for a 10-year period (2006 - 2016), thereby 
establishing the Pietersburg renal dialysis unit. The LDoH pays a 
monthly reimbursement fee to the private partner for the capital cost 
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and services provided by the private partner as stipulated in the PPP 
contractual agreement. The renal dialysis unit provides in-centre HD 
and chronic ambulatory PD to public sector patients from across the 
province. In accordance with other public sector dialysis units, strict 
exclusion criteria are applied when selecting patients for dialysis.[9]
A retrospective cost analysis was conducted covering the period 
2007 - 2012 at the renal dialysis unit. The analysis was conducted 
from the service provider’s perspective. A renal doctor and nurse 
were consulted in order to identify the principal resources required 
to provide HD and PD. The main resources identified included 
both variable (pharmaceuticals and material supplies) and quasi-
fixed (personnel, equipment, utilities and buildings) items. The cost 
data were sourced from both the private partner’s annual audited 
expenditure statements and the hospital’s pharmacy, finance and 
human resources departments. All costs were calculated in South 
African rands (ZAR). Table 1 describes the private and public sector 
key cost parameters and the data sources.
Inclusion and exclusion factors
Since the cost analysis was conducted from the provider’s perspective, 
the indirect costs (incurred ‘privately’ by the patients) to access the 
dialysis unit were not included. The study also excluded the costs 
associated with surgical interventions, HD patients’ access creation, 
PD patients’ abdominal catheter procedures, and hospital admissions.
Data analysis
The derived cost and patient data were captured and analysed using 
Excel version 2010 (Microsoft, USA). The data collected were cleaned 
and necessary follow-ups were made for validation in the case of 
errors and/or outliers before estimating total and unit costs. For 
all the annual cost estimates, a discount rate of 4% was applied to 
account for the devaluation of cost over time.
Some of the cost components were available only in aggregated 
totals for both dialysis modalities. These included capital cost, human 
resources, laboratory tests, blood transfusions, pharmaceutical items, 
Table 1. Cost components and data collection methods (2007 - 2012)
Cost components Data collection methods and data sources
Private partner inputs
Capital costs 
Building cost The private partner’s annual expenditure records contained all the capital costs for the 
project from 2007 to 2012. The buildings were annualised over a period of 30 years. The 





Private partner personnel The private partner provided information on the gross salaries of their employees. This 
included all nursing staff, two clinical technicians, sessional staff and a unit manager. 
Other recurrent costs The private partner records were used to identify other indirect recurrent costs. These 
covered electricity, water, cleaning services, laundry facilities, catering and administration.
HD supplies The annual cost of HD supplies, which included dialysers, blood line set and other medical 
supplies, was determined from the private partner’s annual audited expenditure records. 
Public sector inputs
Recurrent costs 
Public sector personnel The hospital’s human resources department provided personnel salary cost information. 
These included a staff nurse, a medical clerk and medical doctors. The overtime cost for 
the medical officers was excluded.
Pharmaceutical items The pharmacy department provided cost data on ward stock supplied to the renal unit. 
The data included all oral and intravenous medication, as well as medical supplies 
including renal catheters and PD catheters.
Laboratory tests The NHLS provided monthly costs of all laboratory investigations tests ordered by the 
renal unit. 
Blood products The SANBS provided cost data on blood transfusion and related products ordered by the 
renal unit. 
PD supplies The annual PD supplies costs, which included PD fluids, disinfection caps and connecting 
lines, were determined from hospital invoices to suppliers. The cost of the PD supplies also 
included transporting supplies to patients’ homes.
Utilisation data 
Number of patients on chronic HD and PD The renal dialysis unit provided statistics on the average annual number of patients on 
chronic HD and PD. 
Outsourcing fee 
Reimbursement amount The annual reimbursement amount, which is the amount the public sector pays to the 
private partner, was collected from annual audited hospital expenditure reports. The 
reimbursement amount was based on the number of HD sessions per month, which were 
charged at an agreed-upon rate as stipulated in the PPP agreement with annual inflation. 
Outsourcing fee The annual outsourcing fee, which represents the additional cost of the PPP approach, was 
calculated by subtracting the total annual cost of private partner inputs from the annual 
reimbursement amount.
HD = haemodialysis; PD = peritoneal dialysis; NHLS = National Health Laboratory Service; SANBS = South African National Blood Service; PPP = public-private partnership.
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laundry, cleaning and catering and other recurrent costs. To estimate 
the total cost of treating either HD or PD patients, these aggregate 
costs were apportioned to each service using allocation criteria that 
reflect actual resource usage. The standard operating procedures and 
the dialysis guidelines primarily informed the allocation of shared 
costs to HD and PD. Overall, we made the following assumptions in 
disaggregating these costs:
• HD patients are mostly hospital-based and are required to dialyse 
for 4 hours, three times a week. They therefore require 12 visits to 
the renal unit per month.
• PD is mostly done at home, with a single monthly visit to the renal 
unit.
• All patients are on a 6-week acute HD programme before being 
assigned to a dialysis modality.
• The standard procedures for HD and PD in terms of blood 
transfusions and routine laboratory investigations are similar for 
both dialysis modalities.
• The requirement for intravenous medical supplies is greater for 
HD patients than for those on PD because of their frequent visits 
to the dialysis unit and the nature of the dialysis.
Unit cost estimation
A top-down approach was used to arrive at an estimated cost per 
patient (unit costs) for HD and PD. The total annual cost for both HD 
and PD was divided by the annual number of patients on chronic HD 
and PD, respectively, to determine unit costs for each of the 6 years. 
The unit costs for 2012 were converted to US dollars (USD) using 
the official World Bank 2012 exchange rate, which was on average 
1 USD = 8.2 ZAR (in December 2012) to allow for comparison.[10]
Sensitivity analysis
A sensitivity analysis was conducted to test the robustness of the 
estimates by varying the allocation percentage for PD supplies, HD 
supplies, pharmaceutical items and personnel, which contributed 
>70% to the total cost in any given year. The uncertainty was limited 
to personnel cost and the cost of pharmaceutical supplies, which 
were apportioned to PD and HD according to the key assumptions 
described above. The varying of the allocation percentages for 
personnel costs and pharmaceutical items cost by 20% did not impact 
significantly on the overall unit costs estimated for PD and HD.
Ethical considerations
Ethical approval was obtained from the Medunsa Research and Ethics 
Committee at the University of Limpopo, now Sefako Makgatho 
Health Sciences University (ref. no. MREC/M/164/2014).
Results
The number of patients on dialysis increased from 77 in 2007 to 182 
in 2012 (Fig. 1). More than 60% of the patients were on HD.
The total cost of providing PD and HD between 2007 and 2012 
was ZAR174 167 572 (before discounting). The major cost drivers 
were personnel (24%), PD supplies (18%), HD supplies (16%), the 
outsourcing fee (12%) and pharmaceutical supplies (11%) (Table 2). 
In combination, these items accounted for 81% of the total cost.
The annual cost per patient for HD fluctuated between ZAR180 213 
and ZAR215 374 (Table 3), whereas that for PD ranged between 
ZAR228 414 and ZAR264 658. The HD/PD ratio was esti mated to 
be 0.83 in 2012.
Discussion
Given that the Pietersburg Hospital renal dialysis unit is the only 
public health sector dialysis unit in Limpopo, it is not surprising that 
the number of patients on dialysis more than doubled between 2007 
and 2012. Despite the increase in the number of dialysis patients 
highlighted in this study, access to dialysis remains severely limited 
in Limpopo, with an estimated dialysis prevalence of 59 pmp in 
contrast to an average of 189 pmp for SA.[1]
HD was the dominant mode of dialysis, with 69.2% of patients on 
HD in 2012. Similarly, Okpechi et al.[11] estimated a PD proportion 
of 28% for SA,[11] which is higher than the estimated global average 
of 11%.[12] With few exceptions, the PD proportion in African 
countries is low; the figures for Egypt, Morocco, Tunisia and Kenya 
were estimated to be 0.14%, 0.62%, 3.0% and 10%, respectively.[11] 
In less developed countries, poor social circumstances, the cost of 
PD solutions, lack of access to clean water and inadequate sanitation 
hinder the use of PD.[11]
Despite the rationing of dialysis in the public sector, provision of 
dialysis is expensive. The total dialysis cost for ~200 patients in 2012 
was almost ZAR40 million, which used 4.4% of the hospital’s total 
budget. In developed countries, it is estimated that 2 - 3% of health 
expenditure is spent on treatment for patients with ESRD, although 
they account for a small proportion of the total population.[13] 
Dialysis treatment demands a significant portion of scarce financial 
resources while benefiting only a few patients.
Measures to curb the cost of dialysis should be directed at the 
main cost drivers. Personnel cost, PD supplies, HD supplies, the 
outsourcing fee and pharmaceutical supplies were the main cost 
drivers in our study, accounting for 81% of the total dialysis cost. 
This finding concurs with previous studies in which recurrent costs 
as opposed to capital expenditure were reported to be the main cost 
driver.[14] Decision-makers should explore various strategies to reduce 
the cost of dialysis supplies. For instance, the re-use of dialysers, price 
negotiations and reducing import duty taxes for dialysis supplies 
have been proposed as cost-reduction strategies. [3] In terms of the 
personnel cost, the national renal summit proposed a reduction 
of the professional nurse-to-patient ratio from the current 1:4 to 
1:6, coupled with an introduction of a mid-category worker (task 
shifting).[3] Cautious implementation of cost-cutting measures is 
necessary to safeguard the quality of dialysis.
In 2012, the average annual unit costs per patient on HD and PD 
were estimated to be ZAR212 286 (USD25 888) and ZAR255  076 
(USD31 106), respectively. These figures are higher than the 
USD12 000 and USD7 000 for PD and HD, respectively, reported 
by Abu Aisha et al.[6] in 2010. El Matri in 2008 estimated the annual 
cost of HD and PD in SA to be USD20 000 and USD30 000, respec-
tively. [7] Comparison between the various estimates for SA is limited 
by the fact that costing approaches and cost items included were not 
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Fig. 1. Number of patients on PD and HD (2007 - 2012). (PD = peritoneal 
dialysis; HD = haemodialysis.)
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the cost of the PPP approach, contributed 12% to the total cost in 
the present study, and may have contributed to the higher cost 
estimates.
Given the differences in health systems, approaches to costing, 
management protocols, currencies and timing of studies, the 
comparison of raw cost data across countries is considered to be 
complex.[14] However, it is useful to compare costs between countries 
of similar economic development and location. In a systematic review, 
Mushi et al.[5] reported the cost of dialysis in low- and middle-income 
countries. Cost-analysis studies in Chile and Brazil estimated the 
annual cost of HD from a societal perspective to be USD24 461 
and USD30  079, respectively, and that of PD to be USD24 389 and 
USD28  592.[5] The annual cost of HD in African countries ranged 
from USD16 000 in Kenya to USD24 500 in Namibia, USD27 440 
in Tanzania and USD42 784 in Nigeria; the annual cost of PD was 
USD12 000 in Kenya, USD24 500 in Namibia and USD47 970 in 
Nigeria.[5] The annual cost of PD in the present study was higher 
than most of the estimates from other countries, with the exception 
of Nigeria.
Differences between the unit cost for HD and PD and patient 
costs for other services in the health system are worth noting. 
For instance, the annual unit cost for HD and PD is substantially 
higher than the average annual cost per patient-day equivalent at 
Pietersburg Hospital, which was calculated at ZAR13  684 in 2012. 
Similarly, the unit cost for HD and PD is significantly higher than 
the average annual unit cost of providing HIV treatment in a public 
sector institution, which was estimated at ZAR8 705.18 (USD682.2) 
in 2011.[15]
The HD/PD cost ratio (the annual cost per HD patient divided 
by the annual cost per PD patient) has been proposed to compare 
annual cost per patient on the two types of dialysis.[14] Despite the use 
of locally manufactured PD fluids, the annual cost of PD per patient 
was greater than that of HD in any given year, with an HD/PD ratio 
of 0.83 in 2012. This is consistent with previous studies, in which 
PD was more expensive than HD in most developing countries.[16] 
The use of imported PD fluids is commonly cited as the main reason 
for the high PD cost in developing countries.[16] In contrast, we 
confirmed that the PD fluids used in the Pietersburg renal unit were 
locally produced. The additional cost of transporting PD supplies 
across a rural province may have contributed to the high cost of PD 
v. HD.
The PPP approach is proposed as one strategy to increase access 
to dialysis. The outsourcing fee, which represents the additional cost 
of providing dialysis service through the partnership, was identified 
as one of the cost drivers in this study. The outsourcing fee was 
estimated to be ZAR20.259 million over 6 years, representing 11% 
of the total cost. It is difficult to make a judgement on the additional 
cost of the PPP approach, because there is no stipulated agreement 
on the national benchmark or standard for the additional costs 
attached to the partnership approach. Furthermore, according to 
National Treasury, the value-for-money criterion, which states that 
‘the provision of institutional function by a private partner should 
result in net benefit in terms of cost, price, quality, quantity and risk 
transfer’, is recommended for evaluating the PPP approach.[4] The 
risks and benefits of the PPP v. the public sector approach should 
therefore also be measured to comprehensively evaluate the value of 
the partnership.
Study limitations
This study is not without limitations. The health provider’s 
perspective, which considers the direct cost of dialysis provision, 
was used to estimate the cost of dialysis in this study. Because HD is 
conducted at the hospital facility three times a week, by excluding 
its indirect costs the expenditure on HD may be underestimated. 
The dialysis patients in this study were selected using strict 
criteria that prioritised younger patients with less comorbidity; the 
estimates of dialysis cost will therefore apply to such a population. 
The study was conducted more than 6 years ago, so it is possible 
that the situation may have changed since 2012. However, the 
study is still useful for health planners because it provides a 
baseline assessment that outlines the costing approach and the cost 
components included. The fact that the study was conducted in a 
context of a PPP further underscores its importance in the era of 
universal health coverage.
Table 2. Cumulative total cost of running the renal dialysis 
PPP project (2007 - 2012)
Item Cumulative cost (ZAR) %
Personnel 40 802 514 24
PD supplies 30 974 410 18
HD supplies 27 754 244 16
Outsourcing fee 20 258 609 12
Pharmaceutical supplies 18 320 189 11
NHLS (laboratory tests) 8 188 262 5
Maintenance 6 847 342 4
Capital items 5 996 741 4
Administration 3 052 160 2
Catering 2 202 654 1
Other recurrent costs 1 777 755 1
Blood products 1 766 444 1
Cleaning services 1 427 368 1
Laundry services 451 309 0,3
Grand total 169 820 001 100
PPP = public-private partnership; PD = peritoneal dialysis; HD = haemodialysis;  
NHLS = National Health Laboratory Service.
Table 3. Annual unit cost of HD and PD (2007 - 2012)




cost for HD HD patients, n Cost per HD patient
Total annual cost 
for PD PD patients, n Cost per PD patient
2007 10 768 706 50 215 374 7 145 775 27 264 658 0.81
2008 13 690 004 72 190 139 9 593 388 42 228 414 0.83
2009 16 827 559 86 195 669 11 578 889 50 231 578 0.84
2010 18 922 398 105 180 213 12 685 071 55 230 638 0.78
2011 23 877 183 114 209 449 14 414 562 61 236 304 0.89
2012 26 748 015 126 212 286 14 284 251 56 255 076 0.83
HD = haemodialysis; PD = peritoneal dialysis.
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Conclusions
The provision of dialysis for patients with ESRD is a large economic 
burden for the health system. In this study we estimated the annual 
cost for HD and PD in 2012 to be ZAR212 286 (USD25 888) and 
ZAR255 076 (USD31 106) per patient, respectively. Despite the 
fact that PD is considered a less resource-intensive dialysis therapy 
than HD, the annual PD cost was greater than that of HD in any 
given year. In order to improve efficiency of dialysis, we should 
prioritise measures to mitigate the main cost drivers, which included 
personnel cost, PD supplies, HD supplies, the outsourcing fee and 
pharmaceutical supplies. Furthermore, it is imperative to develop 
a comprehensive primary healthcare-based approach to preventing 
CKD. The value of methodologically sound costing studies to inform 
policy on the prevention and management of CKD in developing 
countries cannot be over-emphasised.
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